Use of methyl-CCNU and procarbazine in advanced malignant melanoma resistant to DTIC therapy

M. S. Didolkar; R. R. Baffi; R. Catane; J. Kaufman; E. D. Holyoke

Use of methyl-CCNU and procarbazine in advanced malignant melanoma resistant to DTIC therapy

M. S. Didolkar, R. R. Baffi, R. Catane, J. Kaufman, E. D. Holyoke

School of Medicine

Research output: Contribution to journal › Letter › peer-review

2 Scopus citations

Abstract

When used singly as first agents, both drugs have shown some effect in previous reports; however, when used in combination after failure with DTIC therapy, the responses have been very poor. It appears that 'second attempt' chemotherapy in advanced malignant melanoma results in poor response.

Original language	English (US)
Pages (from-to)	1738-1739
Number of pages	2
Journal	Cancer Treatment Reports
Volume	61
Issue number	9
State	Published - Dec 1 1977

ASJC Scopus subject areas

Oncology
Cancer Research

Cite this

@article{da05ab4f8ca24d0990e0c3c0ff18f5b8,

title = "Use of methyl-CCNU and procarbazine in advanced malignant melanoma resistant to DTIC therapy",

abstract = "When used singly as first agents, both drugs have shown some effect in previous reports; however, when used in combination after failure with DTIC therapy, the responses have been very poor. It appears that 'second attempt' chemotherapy in advanced malignant melanoma results in poor response.",

author = "Didolkar, {M. S.} and Baffi, {R. R.} and R. Catane and J. Kaufman and Holyoke, {E. D.}",

year = "1977",

month = dec,

day = "1",

language = "English (US)",

volume = "61",

pages = "1738--1739",

journal = "Journal of the National Cancer Institute",

issn = "0027-8874",

publisher = "Oxford University Press",

number = "9",

}

TY - JOUR

T1 - Use of methyl-CCNU and procarbazine in advanced malignant melanoma resistant to DTIC therapy

AU - Didolkar, M. S.

AU - Baffi, R. R.

AU - Catane, R.

AU - Kaufman, J.

AU - Holyoke, E. D.

PY - 1977/12/1

Y1 - 1977/12/1

N2 - When used singly as first agents, both drugs have shown some effect in previous reports; however, when used in combination after failure with DTIC therapy, the responses have been very poor. It appears that 'second attempt' chemotherapy in advanced malignant melanoma results in poor response.

AB - When used singly as first agents, both drugs have shown some effect in previous reports; however, when used in combination after failure with DTIC therapy, the responses have been very poor. It appears that 'second attempt' chemotherapy in advanced malignant melanoma results in poor response.

UR - http://www.scopus.com/inward/record.url?scp=0017604144&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0017604144&partnerID=8YFLogxK

M3 - Letter

C2 - 597824

AN - SCOPUS:0017604144

VL - 61

SP - 1738

EP - 1739

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

SN - 0027-8874

IS - 9

ER -

Use of methyl-CCNU and procarbazine in advanced malignant melanoma resistant to DTIC therapy

Abstract

ASJC Scopus subject areas

Other files and links

Fingerprint

Cite this